All In Biotech

Drug Trial Radar · NCT06780085

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

May 13, 2025

Primary completion

Mar 12, 2032

Study completion Mar 12, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Jan 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to know if 2 antibody drug conjugates (ADCs) can help treat metastatic nonsquamous NSCLC that did not respond (get smaller or go away) to treatment. An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells. Researchers will compare 2 different ADCs (the study treatments) to chemotherapy in this study. The goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * How many people have the cancer respond to the study treatments

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • Raludotatug DeruxtecanBiological

    IV Infusion

  • Ifinatamab DeruxtecanBiological

    IV Infusion

  • DocetetaxelDrug

    IV Infusion

  • 5-hydroxytryptamine subtype 3 receptor antagonistDrug

    Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion

  • Neurokinin-1 receptor antagonistDrug

    Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion

  • CorticosteroidDrug

    Administered as a rescue medication per approved product label before R-DXd or I-DXd infusion, and for 3 days starting 1 day prior to docetaxel administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to approximately 81 months
  2. Percentage of Participants with at Least One Adverse Event (AE)Time frame: Up to approximately 81 months
  3. Percentage of Participants Who Discontinued Medication Due to an AETime frame: Up to approximately 24 months

Locations

36 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Kentucky Chandler Medical Center ( Site 0019)

    Lexington, Kentucky

  • MedStar Franklin Square Medical Center ( Site 0033)

    Baltimore, Maryland

  • AHN Cancer Institute - Allegheny General ( Site 9501)

    Pittsburgh, Pennsylvania

  • Texas Oncology - DFW ( Site 8003)

    Dallas, Texas

  • Centro de Estudios Clínicos SAGA ( Site 0161)

    Santiago, Region M. de Santiago, Chile

  • Fundación Arturo López Pérez ( Site 0160)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 0162)

    Santiago, Region M. de Santiago, Chile

  • Charite-Universitaetsmedizin Berlin ( Site 0191)

    Berlin, Germany

  • Universitaetsklinik Tuebingen ( Site 0192)

    Tübingen, Baden-Wurttemberg, Germany

  • European Interbalkan Medical Center ( Site 0205)

    Thessaloniki, Greece

  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 0204)

    Athens, Attica, Greece

  • Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 0063)

    Kecskemét, Bács-Kiskun county, Hungary

  • Petz Aladar Egyetemi Oktato Korhaz ( Site 0062)

    Győr, Győr-Moson-Sopron, Hungary

  • Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061)

    Szolnok, Jász-Nagykun-Szolnok, Hungary

  • Református Pulmonológiai Centrum ( Site 0064)

    Törökbálint, Pest County, Hungary

  • Rambam Health Care Campus ( Site 0076)

    Haifa, Israel

  • Shaare Zedek Medical Center ( Site 0075)

    Jerusalem, Israel

  • Meir Medical Center ( Site 0071)

    Kfar Saba, Israel

  • Rabin Medical Center ( Site 0074)

    Petah Tikva, Israel

  • Sheba Medical Center ( Site 0070)

    Ramat Gan, Israel

  • Sourasky Medical Center ( Site 0077)

    Tel Aviv, Israel

  • Azienda Ospedaliera Universitaria Careggi ( Site 0173)

    Florence, Italy

  • Ospedale San Raffaele. ( Site 0171)

    Milan, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)

    Roma, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)

    Milan, Lombardy, Italy

  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 0153)

    Poznan, Greater Poland Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)

    Warsaw, Masovian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)

    Gdansk, Pomeranian Voivodeship, Poland

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie ( Site 0152)

    Koszalin, West Pomeranian Voivodeship, Poland

  • Hospital Universitario Quiron Madrid ( Site 0091)

    Madrid, Spain

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0090)

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 0141)

    Adana, Turkey (Türkiye)

  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0140)

    Ankara, Turkey (Türkiye)

  • Ankara Bilkent Şehir Hastanesi. ( Site 0142)

    Ankara, Turkey (Türkiye)

  • I. U. Cerrahpasa Tip Fakultesi ( Site 0144)

    Istanbul, Turkey (Türkiye)

  • Ege Universitesi Hastanesi ( Site 0143)

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.